G1 Therapeutics Inc (GTHX)
4.49
+0.05
(+1.13%)
USD |
NASDAQ |
May 03, 16:00
4.58
+0.09
(+2.00%)
Pre-Market: 20:00
G1 Therapeutics Revenue (Quarterly): 14.87M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 14.87M |
September 30, 2023 | 12.30M |
June 30, 2023 | 42.39M |
March 31, 2023 | 12.95M |
December 31, 2022 | 10.25M |
September 30, 2022 | 23.58M |
June 30, 2022 | 10.57M |
March 31, 2022 | 6.902M |
Date | Value |
---|---|
December 31, 2021 | 5.796M |
September 30, 2021 | 4.858M |
June 30, 2021 | 6.604M |
March 31, 2021 | 14.22M |
December 31, 2020 | 16.55M |
September 30, 2020 | 26.60M |
June 30, 2020 | 2.14M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.14M
Minimum
Jun 2020
42.39M
Maximum
Jun 2023
14.04M
Average
12.30M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
Amicus Therapeutics Inc | 115.08M |
Geron Corp | 0.304M |
Palatin Technologies Inc | 2.034M |
Oragenics Inc | -- |
TG Therapeutics Inc | 63.47M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -10.88M |
Total Expenses (Quarterly) | 23.80M |
EPS Diluted (Quarterly) | -0.21 |
Enterprise Value | 203.78M |
Gross Profit Margin (Quarterly) | 91.56% |
Profit Margin (Quarterly) | -73.14% |
Earnings Yield | -21.16% |
Normalized Earnings Yield | -21.16 |